Justin Kim
Stock Analyst at Oppenheimer
(1.21)
# 1,617
Out of 4,479 analysts
31
Total ratings
36%
Success rate
-11.36%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $54.84 | +93.29% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $34.80 | +150.00% | 5 | Feb 29, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $75 → $79 | $34.98 | +125.84% | 5 | Jan 30, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $34.93 | -25.57% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $3.25 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $3.43 | +395.63% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $5.43 | - | 5 | Nov 4, 2022 | |
| PHVS Pharvaris | Maintains: Outperform | $48 → $22 | $16.85 | +30.56% | 2 | Aug 23, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $6.55 | - | 4 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $45.14 | +30.70% | 1 | Jul 18, 2022 |
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $54.84
Upside: +93.29%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $34.80
Upside: +150.00%
Apellis Pharmaceuticals
Jan 30, 2024
Maintains: Outperform
Price Target: $75 → $79
Current: $34.98
Upside: +125.84%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $34.93
Upside: -25.57%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.25
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $3.43
Upside: +395.63%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.43
Upside: -
Pharvaris
Aug 23, 2022
Maintains: Outperform
Price Target: $48 → $22
Current: $16.85
Upside: +30.56%
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.55
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $45.14
Upside: +30.70%